Navidea biopharmaceuticals announces additional bridge loan funding

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on july 1, 2022, its largest shareholder and vice chair of the board of directors, john k. scott, jr., funded an additional $1.0 million under the secured bridge loan that was executed on april 10, 2022. dr. michael rosol, chief medical officer for navidea, said,
NAVB Ratings Summary
NAVB Quant Ranking